Arineta News
8 articles
growth-positive
הסטארט-אפ הישראלי ארינטה ניהל מגעים למכירתו ב-300 מיליון דולר
Arineta, an Israeli medical device startup, has developed a specialized CT scanner for cardiologists. The company recently engaged in negotiations for its acquisition, valued at approximately $300 million. The discussions were held with two major healthcare corporations, Abbott and Johnson & Johnson. This comes about a year after a previous sale deal was canceled due to the war. Since then, Arineta has managed to double its revenues, indicating a positive growth trajectory. The article highlights the companys strategic move towards being acquired by industry giants, reflecting its significant valuation and market potential.
Acquired-by
growth-positive
הסטארט-אפ הישראלי ארינטה ניהל מגעים למכירתו ב-300 מיליון דולר
Israeli medical device startup Arineta, which developed a specialized CT scanner for cardiologists, has been in negotiations for its acquisition at a valuation of approximately $300 million. The discussions are with two major healthcare corporations, Abbott and Johnson & Johnson. This comes a year after a previous sale deal was canceled due to war-related disruptions. Since then, Arineta has managed to double its revenues, indicating a strong growth trajectory. The potential acquisition by such prominent companies highlights the strategic value of Arinetas technology in the medical field.
Acquired-by
growth-positive
Heart Disease & COVID-19: An Epidemic Within a Pandemic Creates a Cardiac Conundrum
The COVID-19 pandemic is creating a new generation of cardiac patients, leading to a surge in demand for cardiology services and technology. GE Healthcare, with over 40 years of experience in Cardiology, is at the forefront of this change. The companys technologies, such as ECG and ultrasound devices, are being used globally to diagnose and treat COVID-19 patients. The pandemic has also highlighted the need for patient care beyond hospital walls, and GE Healthcare is developing new technologies and solutions to meet this demand. Despite the challenges, the company remains committed to improving efficiency, productivity, and clinical outcomes.
CustomersExpand
growth-positive
Siemens Joins GE With Launch of Cardiac CT Scanners
Siemens Healthineers has launched a CT scanner optimized for cardiac scanning at the American College of Cardiology conference. The new CT scanner, a version of Siemens Go platform, is intended primarily for sale to outpatient centers and is priced under $800,000. The launch reflects the increasing use of CT in cardiology. The ADVANCE study, released at the conference, showed low rates of events in all patients using CT-based fractional flow reserve, indicating that patients can use CT to determine if they have a low risk of adverse cardiovascular events. Siemens cardiac system is built on the go.Top CT platform and features applications designed exclusively for cardiological scanning. It allows for a low total cost of ownership and increases access to valuable procedures. The system also maintains the full radiological capability of the underlying go.Top platform.
Customers
growth-positive
New Cardiovascular CT Technology Entering the Market
The article discusses recent advancements in cardiac computed tomography angiography (CCTA) imaging technology, specifically focusing on two CT systems: the GE Healthcare Cardiographe and the Canon (formerly Toshiba) Aquilion Precision. The Cardiographe, developed by Israeli start-up company Arineta in partnership with GE Healthcare, offers improved coronary CT angiography and gained FDA clearance in 2017. The Aquilion Precision, the first CT system to offer a 0.25 mm resolution, provides better visualization of tiny structures in coronary plaques and stent struts. The article also mentions other new CT scanners on the market, including the GE Revolution Frontier and Siemens Somatom go.All and go.Top. Additionally, it highlights the use of fractional flow reserve computed tomography (FFR-CT) for noninvasive assessment of coronary lesions. Several vendors, including GE Healthcare, have partnered with HeartFlow to offer FFR-CT technology. Overall, the article focuses on advancements in cardiac CT technology and its potential impact on patient care.
Partners
growth-positive
GE orders 12 CT systems from Israeli co Arineta
Arineta has received its first commercial order for its special CE cardiac scanner from GE Healthcare, with an order of 12 systems. The revenue division has not been disclosed, but Arineta is expected to gain several million dollars from the order. The agreement between Arineta and GE states that GE will order more systems every year. Arinetas scanner uses two sources of radiation to scan the heart and scans the entire heart at once, making it more successful and cheaper than other systems. Arineta is supported by investors and is planning to raise $20-30 million to build a production plant.
CustomersInvestment
growth-positive
Arineta gets FDA nod for cardiology CT device
Arineta, a medical device company, has received FDA approval for its new cardiac mapping CT device. The company has raised $13.5 million in investments, primarily from private investors including the Richter family and Dr. Shmuel Levinger. Arineta has signed a strategic agreement with GE Healthcare to market its product. The CEO of Arineta expects to sign deals and increase sales in the coming year. The companys device is cheaper than other CT devices and offers a faster and more accurate diagnosis of heart disease. Arineta plans to target invasive cardiologists and expand its facilities. The FDA approval was given without clinical trials, but the company has conducted tests on over 200 people. The company aims to become a leading brand in cardiac imaging.
InvestmentPartnersExpand
growth-positive
Cardiac CT co Arineta raises $10m
Arineta Ltd., a cardiac CT developer, has raised $10 million from Israeli and foreign private investors. The funding will allow the company to complete the development of its proprietary CT scanner for cardiology. Arineta has a cooperation agreement with GE Healthcare to market the product. The company plans to bring the product to market in 2014. The CEO of Arineta confirmed the funding but did not disclose the amount. The collaboration with large companies at an early stage to customize the product and gain their support is becoming popular due to the length and cost of the product development process. Arinetas scanner offers cardiovascular diagnostics at an earlier stage and lower cost compared to other devices.
Investment
